



26 June 2024

Sydney, Australia

Nyrada Signs Strategic Partnership with US Brain Injury Detection and Monitoring Company

Highlights:

- Nyrada signs strategic partnership agreement with Rebion to advance brain injury therapies and outcomes.
 - Partnership will facilitate joint research and development projects to improve traumatic brain injury outcomes, along with non-dilutive funding opportunities.
 - Over 70 million people worldwide experience a traumatic brain injury each year¹.
 - The estimated annual healthcare cost of non-fatal traumatic brain injury is over \$40 billion in the US².
-

Nyrada Inc (ASX:NYR) (“Nyrada or “Company”), a drug development company specialising in novel small molecule therapeutics is pleased to announce a strategic partnership with Rebiscan Inc., operating as ‘Rebion’.

[Rebion](#) is a Boston-based medical device development company leveraging its Neural Performance Scanning (NPS) technology to identify and monitor functional impairments in the brain stemming from disease or injury. Nyrada and Rebion will collaborate on advancing therapies and outcomes for traumatic brain injury sufferers. This collaboration spans joint research, conference presentations, and applications for non-dilutive funding grants.

Nyrada CEO James Bonnar commented: “Nyrada is excited to partner with Rebion. This partnership will expand the capacities of both companies, providing a platform to achieve our shared ambition of improving health outcomes for the millions of patients that suffer traumatic brain injury each year. We look forward to working with the team at Rebion and realising the opportunities before us.”

Rebion CEO and Managing Director Jeff Craig added: “This partnership is a win-win for both companies. It will allow us to leverage our complementary capabilities to achieve important diagnostic, therapeutic, and commercial outcomes. The future is exciting.”

¹ <https://pubmed.ncbi.nlm.nih.gov/33947273/>

² <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026675/>



The traumatic brain injury market is large and rapidly growing, with no current FDA-approved therapies. Over 70 million people worldwide experience a traumatic brain injury each year, and the estimated annual healthcare cost of non-fatal traumatic brain injuries is over US\$40 billion in the US alone.

Under its Brain Injury Program, Nyrada is developing NYR-BI03, a first in class neuroprotective treatment for both stroke and traumatic brain injury. In February 2024, the Company disclosed preclinical stroke study [results](#) showing that NYR-BI03 provided a statistically significant level of neuroprotection, rescuing 42% of brain injury in the penumbra region in treated animals.

A preclinical study of NYR-BI03's efficacy in traumatic brain injury is currently being conducted at the [Walter Reed Army Institute of Research \(WRAIR\)](#). NYR-BI03 is also currently undergoing preclinical Good Laboratory Practice (GLP) safety tests, a pre-requisite for an in-human Phase I clinical trial scheduled to commence in late 2H2024.

A mid-term goal of this Nyrada-Rebion partnership is to conduct a joint study assessing the efficacy of Nyrada's brain injury therapy with Rebion's brain injury detection and monitoring capabilities; potentially as part of Nyrada's Phase II trial of NYR-BI03³ currently scheduled for CY2025.

There are no immediate financial implications for Nyrada from entering this partnership. However, any material costs or benefits arising from collaborative activities, including discoveries or grants, will be communicated to the market.

-ENDS-

³ Subject to satisfactory completion of GLP and Phase I trials.



About Nyrada Inc

Nyrada is a drug discovery and development company specialising in novel small molecule. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a drug to treat brain injury, specifically traumatic brain injury and stroke, and a cholesterol lowering drug. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.

Investor & Corporate Enquiries:

Dimitri Burshtein
T: +61 2 9498 3390
E: info@nyrada.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: +61 2 8234 0111
E: cstrong@citadelmagnus.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.